ProShares Ultra Nasdaq Biotechnology Rating $111.11 +4.29 (+4.02%) Closing price 03:56 PM EasternExtended Trading$111.16 +0.05 (+0.05%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsSEC Filings ProShares Ultra Nasdaq Biotechnology Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BIB Aggregate RatingModerate Buy 2.66Holdings in BIB have an aggregate rating of Moderate Buy based on 427 analyst ratings issued in the past year covering 19 companies (34.0% of the portfolio).BIB Aggregate Price Target$111.11High Prediction$111.11Average Prediction$111.11Low Prediction$111.11Holdings in BIB have an aggregate price target of $111.11 and a range of $111.11 to $111.11 covering 19 companies (34.0% of the portfolio).BIB Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy2 Buy rating(s)Moderate Buy13 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by ProShares Ultra Nasdaq Biotechnology Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 19 BIB Holdings ExportWeight In ETFCompanyShare PriceConsensus RatingConsensus Price TargetPossible UpsideNumber of RatingsMarketRank™Indicator(s)ViewRatings4.78%GILDGilead Sciences$157.37+2.5%Moderate Buy$159.33 1.2%293.0699 of 5 starsTrending NewsAnalyst ForecastAnalyst Revision4.58%AMGNAmgen$434.03+1.9%Hold$387.93 -10.6%303.6819 of 5 starsTrending NewsAnalyst ForecastAnalyst RevisionGap Up4.43%VRTXVertex Pharmaceuticals$508.75+2.1%Moderate Buy$579.81 14.0%283.9967 of 5 starsGap Up3.06%MRNAModerna$236.50+4.5%Hold$101.45 -57.1%261.784 of 5 starsTrending NewsAnalyst Forecast2.93%REGNRegeneron Pharmaceuticals$796.34+2.3%Moderate Buy$845.21 6.1%314.5165 of 5 starsTrending NewsAnalyst UpgradeInsider TradeGap Up1.68%RVMDRevolution Medicines$189.26-2.2%Moderate Buy$234.81 24.1%243.0686 of 5 starsTrending NewsAnalyst Forecast1.58%ILMNIllumina$267.93-1.4%Hold$225.94 -15.7%182.9424 of 5 starsAnalyst Forecast1.28%BIIBBiogen$235.35+1.1%Moderate Buy$236.04 0.3%322.5114 of 5 starsAnalyst Upgrade1.17%ALNYAlnylam Pharmaceuticals$234.03+4.3%Moderate Buy$364.95 55.9%264.173 of 5 starsTrending NewsAnalyst ForecastGap Up0.99%ARGXargenex$846.27+3.4%Moderate Buy$1,151.95 36.1%304.7374 of 5 starsAnalyst ForecastGap Up0.99%RPRXRoyalty Pharma$59.62+1.1%Buy$61.57 3.3%83.4305 of 5 stars0.98%ROIVRoivant Sciences$34.04+1.2%Moderate Buy$45.64 34.1%142.8014 of 5 starsPositive NewsAnalyst Downgrade0.91%UTHRUnited Therapeutics$541.51+0.3%Moderate Buy$642.69 18.7%144.1537 of 5 starsTrending NewsAnalyst ForecastInsider Trade0.90%INCYIncyte$113.27+1.5%Moderate Buy$128.20 13.2%253.8564 of 5 starsAnalyst Forecast0.88%GHGuardant Health$165.88+1.8%Moderate Buy$190.00 14.5%252.4085 of 5 starsAnalyst Forecast0.87%INSMInsmed$99.21+1.5%Moderate Buy$200.30 101.9%252.8551 of 5 starsAnalyst ForecastOptions VolumeAnalyst Revision0.78%VTRSViatris$18.22+4.5%Moderate Buy$20.50 12.5%92.9569 of 5 starsAnalyst Upgrade0.66%MEDPMedpace$628.60+1.9%Hold$607.73 -3.3%132.7222 of 5 starsUpcoming Earnings0.59%JAZZJazz Pharmaceuticals$214.42+2.3%Buy$291.25 35.8%204.2782 of 5 stars This page (NASDAQ:BIB) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going t...Decentralized Masters | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares Ultra Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share ProShares Ultra Nasdaq Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
